We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

DNASTAR Announces Release of Lasergene 11

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

DNASTAR® has announced the release of Lasergene 11. The major news in this release is that Lasergene, the most published sequence analysis software in peer reviewed journals for each of the past 28 years, is now available on the Amazon Cloud.

Other significant improvements to Lasergene, which is an integrated suite of software for Sanger and next-generation sequence assembly and analysis, include the introduction of a new application, MegAlign Pro, which includes the Muscle sequence alignment algorithm; new 16S rRNA and host-viral integration workflows in support of next-generation sequencing platforms and technologies; enhanced Copy Number Variation analysis capability, and numerous improvements to Protean 3D, the integrated protein structure, sequence, and bioinformatic application within the Lasergene software suite.

Tom Schwei, Vice President and General Manager of DNASTAR, said, “DNASTAR has been breaking new ground in the molecular biology software market for the past 30 years. We were the first commercial company to enter this market and we are now the first company to have an integrated desktop computer/cloud offering that includes all of our software capabilities on both the ground and the cloud. By using the cloud, our customers can more easily collaborate globally; access powerful hardware for occasional large projects that require it; run as many assembly projects as desired sequentially or concurrently; and take full advantage of the flexibility offered by our software for any application anywhere, anytime. We are very pleased to take this major step forward to support life scientists. We look forward to continuing to lead the market with additional breakthrough innovations in the future.”